COVID-19 course in granulomatosis with polyangiitis: single center experience with review of the literature

EKSIN, MEHMET AKIF; Güven, Serdar Can; Özdemir Ulusoy, Bahar; Akyüz Dağlı, Pınar; kucuksahin, orhan; Armagan, Berkan; erden, abdulsamet; Omma, Ahmet

doi:10.55730/1300-0144.5389

COVID-19 course in granulomatosis with polyangiitis: single center experience with review of the literature

Berkan ARMAĞAN, (Ankara Şehir Hastanesi, Romatoloji Kliniği, Ankara, Türkiye)

Mehmet Akif EKSİN, (Ankara Şehir Hastanesi, Romatoloji Kliniği, Ankara, Türkiye)

Serdar Can GÜVEN, (Ankara Şehir Hastanesi, Romatoloji Kliniği, Ankara, Türkiye)

Bahar ÖZDEMİR, (Ankara Şehir Hastanesi, Romatoloji Kliniği, Ankara, Türkiye)

Pınar AKYÜZ DAĞLI, (Ankara Şehir Hastanesi, Romatoloji Kliniği, Ankara, Türkiye)

Orhan KÜÇÜKŞAHİN, (Ankara Yıldırım Beyazıt Üniversitesi, Dahiliye Bölümü, Romatoloji Anabilim Dalı, Ankara, Türkiye)

Ahmet OMMA, (Ankara Şehir Hastanesi, Romatoloji Kliniği, Ankara, Türkiye)

Abdulsamet ERDEN (Ankara Şehir Hastanesi, Romatoloji Kliniği, Ankara, Türkiye)

Turkish Journal of Medical Sciences

7 0

Yıl: 2022 Cilt: 52 Sayı: 4 Sayfa Aralığı: 899 - 909 Metin Dili: İngilizce DOI: 10.55730/1300-0144.5389 İndeks Tarihi: 14-12-2022

COVID-19 course in granulomatosis with polyangiitis: single center experience with review of the literature

Öz:

Background/aim: Coronavirus disease 2019 (COVID-19) shares some clinical features with new-onset granulomatosis with polyangiitis (GPA) or GPA flare that may lead to a challenge in differential diagnosis. To date, little is known whether GPA can be induced by COVID-19. Herein, we aimed to seek the frequency and mortality rates of COVID-19 in our GPA cohort, and along with the literature cases, to evaluate clinical features and treatments of GPA patients with COVID-19. We also tried to identify clinical features of COVID-19 induced GPA. Materials and methods: As of July 2021, we conducted a systematic literature review using different spelling combinations of “COVID-19 and GPA” in the PUBMED database. In total, 18 cases were found in the literature, 6 of them had COVID-19 induced GPA. The remaining 12 of literature cases and 6 cases in our GPA cohort (n = 81) had a COVID-19 infection while followed-up with GPA. We grouped these 18 patients as GPA+COVID-19. Results: The frequency of COVID-19 was 7.4% in GPA cohort and mortality rate was 33% in GPA patients with COVID-19. The most common symptoms of GPA+COVID-19 patients were fever, cough, arthralgia/myalgia, and malaise. The most frequent treatments for GPA before the COVID-19 infection were steroids (72%) and rituximab (56%). Three patients who received rituximab also had COVID-19 reinfection. In the literature cases, mortality was observed in 4 (22%) of 18 patients with GPA+COVID-19. The most common symptoms of COVID-19 induced GPA were dyspnea, fever and cough. Conclusion: In our GPA cohort, we observed a higher mortality rate compared to global WHO data. In patients followed up with GPA, rituximab treatment may be precarious for both COVID-19 disease and reinfection. Our study also provided some clues about the diagnostic challenge of GPA induced by COVID-19.

Anahtar Kelime: Coronavirus disease 2019 severe acute respiratory syndrome coronavirus 2 granulomatosis with polyangiitis Wegener’s granulomatosis rituximab

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. The Journal of The American Medical Association. 2020; 324 (8): 782-793. doi: 10.1001/jama.2020.12839
2. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. The Journal of The American Medical Association. 2020; 323 (13): 1239-1242. doi: 10.1001/jama.2020.2648
3. Zheng Z, Peng F, Xu B, Zhao J, Liu H et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. Journal of Infection. 2020; 81 (2): e16-e25. doi: 10.1016/j.jinf.2020.04.021
4. Zhou F, Yu T, Du R, Fan G, Liu Y et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395 (10229): 1054-1062. doi: 10.1016/S0140-6736(20)30566-3
5. Jagiello P, Gross WL, Epplen JT. Complex genetics of Wegener granulomatosis. Autoimmun Reviews. 2005; 4 (1): 42-47. doi: 10.1016/j.autrev.2004.06.003
6. Lind E, Jameson A, Kurban E. Fulminant granulomatosis with polyangiitis presenting with diffuse alveolar haemorrhage following COVID-19. BMJ Case Rep. 2021; 14 (6): e242628. doi: 10.1136/bcr-2021-242628
7. Luqmani RA, Bacon PA, Beaman M, Scott DG, Emery P et al. Classical versus non-renal Wegener’s granulomatosis. Quarterly Journal of Medicine. 1994; 87 (3): 161-167.
8. Schilder AM. Wegener’s Granulomatosis vasculitis and granuloma. Autoimmun Reviews. 2010; 9 (7): 483-487. doi: 10.1016/j.autrev.2010.02.006
9. Akiyama S, Hamdeh S, Micic D, Sakuraba A. Response to: ‘Correspondence on ‘Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis’’ by Yang et al. Annals of the Rheumatic Diseases. 2021. doi: 10.1136/annrheumdis-2021-219855
10. Ozdemir B, Erden A, Guven SC, Armagan B, Apaydin H et al. COVID-19 and eosinophilic granulomatosis with polyangiitis or COVID-19 mimicking eosinophilic granulomatosis with polyangiitis? Rheumatology International. 2021; 41 (8): 1515- 1521. doi: 10.1007/s00296-021-04896-2
11. Pablos JL, Abasolo L, Alvaro-Gracia JM, Blanco FJ, Blanco R et al. Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases. Annals of the Rheumatic Diseases. 2020; 79 (9): 1170-1173. doi: 10.1136/annrheumdis-2020-217763
12. Pablos JL, Galindo M, Carmona L, Lledo A, Retuerto M et al. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. Annals of the Rheumatic Diseases. 2020; 79 (12): 1544-1549. doi: 10.1136/ annrheumdis-2020-218296
13. Strangfeld A, Schafer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Annals of the Rheumatic Diseases. 2021; 80 (7): 930-942. doi: 10.1136/annrheumdis-2020-219498
14. de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016; 14 (8): 523-534. doi: 10.1038/ nrmicro.2016.81
15. Haberman R, Axelrad J, Chen A, Castillo R, Yan D et al. Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York. New England Journal of Medicine. 2020; 383 (1): 85-88. doi:10.1056/NEJMc2009567
16. Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Annals of the Rheumatic Diseases. 2020; 79 (5): 667-668. doi: 10.1136/ annrheumdis-2020-217424
17. Guo L, Ren L, Yang S, Xiao M, Chang et al. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). Clinical Infectious Diseases. 2020; 71 (15): 778- 785. doi: 10.1093/cid/ciaa310
18. Russell B, Moss C, George G, Santaolalla A, Cope A et al. Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence. Ecancermedicalscience. 2020; 14: 1022. doi: 10.3332/ ecancer.2020.1022
19. Selvaraj V, Moustafa A, Dapaah-Afriyie K, Birkenbach MP. COVID-19-induced granulomatosis with polyangiitis. BMJ Case Rep. 2021; 14 (3): e242142. doi: 10.1136/bcr-2021-242142
20. Izci Duran T, Turkmen E, Dilek M, Sayarlioglu H, Arik N. ANCA-associated vasculitis after COVID-19. Rheumatology International. 2021; 41 (8): 1523-1529. doi: 10.1007/s00296- 021-04914-3
21. Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG et al. The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheumatology. 1990; 33 (8): 1101-1107. doi: 10.1002/ art.1780330807
22. Guilpain P, Le Bihan C, Foulongne V, Taourel P, Pansu N et al. Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia. Annals of the Rheumatic Diseases. 2021; 80 (1): e10. doi:10.1136/annrheumdis-2020-217549
23. Hakroush S, Franz J, Larsen J, Korsten P, Winkler MS, Tampe B. Repeated false-negative tests delayed diagnosis of COVID-19 in a case with granulomatosis with polyangiitis under maintenance therapy with rituximab and concomitant influenza pneumonia. Annals of the Rheumatic Diseases. 2020. doi: 10.1136/annrheumdis-2020-218491
24. Daniel P, Raad M, Waked R, Choucair J, Riachy M, Haddad F. COVID-19 in a Patient Treated for Granulomatosis with Polyangiitis: Persistent Viral Shedding with No Cytokine Storm. European Journal of Case Reports in Internal Medicine. 2020; 7 (10): 001922. doi: 10.12890/2020_001922
25. Gulati K, Prendecki M, Clarke C, Willicombe M, McAdoo S. COVID-19 Reinfection in a Patient Receiving Immunosuppressive Treatment for Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatology. 2021; 73 (6): 1091-1092. doi: 10.1002/art.41671
26. Fallet B, Kyburz D, Walker UA. Mild Course of COVID-19 and Spontaneous Virus Clearance in a Patient With Depleted Peripheral Blood B Cells Due to Rituximab Treatment. Arthritis Rheumatology. 2020; 72 (9): 1581-1582. doi: 10.1002/ art.41380
27. Leipe J, Wilke EL, Ebert MP, Teufel A, Reindl W. Long, relapsing, and atypical symptomatic course of COVID-19 in a B-cell-depleted patient after rituximab. Semin Arthritis Rheumatology. 2020; 50 (5): 1087-1088. doi: 10.1016/j. semarthrit.2020.06.013
28. Friedman MA, Winthrop KL. Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab. Annals of the Rheumatic Diseases. 2021. doi: 10.1136/ annrheumdis-2021-220088
29. Shenavandeh S, Sefidbakht S, Iranpour P, Teimouri A, Hooshmandi S et al. COVID-19 and granulomatosis with polyangiitis (GPA): a diagnostic challenge. Rheumatology (Oxford). 2020; 59 (8): 2170-2171. doi: 10.1093/rheumatology/ keaa326
30. Ince B, Bektas M, Koca N, Agargun BF, Zarali S et al. A single center survey study of systemic vasculitis and COVID-19 during the first months of pandemic. Turkish Journal of Medical Sciences. 2021; 51 (5): 2243-2247. doi: 10.3906/sag- 2010-267
31. Rodriguez-Pla A, Vikram HR, Khalid V, Wesselius LJ. COVID-19 pneumonia in a patient with granulomatosis with polyangiitis on rituximab: case-based review. Rheumatology International. 2021; 41 (8) :1509-1514. doi: 10.1007/s00296- 021-04905-4
32. Masiak A, Nowakowski S, Zdrojewski Z. SARS-CoV-2 infection associated with active granulomatosis with polyangiitis. Polish Archives of Internal Medicine. 2021; 131 (6): 563-565. doi: 10.20452/pamw.15993
33. Bressler MY, Pathak N, Cervellione K, Bagheri F, Epstein E et al. New Onset Granulomatosis with Polyangiitis Associated with COVID-19. Case Reports in Dermatological Medicine. 2021; 2021: 8877292. doi: 10.1155/2021/8877292
34. Hussein A, Al Khalil K, Bawazir YM. Anti-Neutrophilic Cytoplasmic Antibody (ANCA) Vasculitis Presented as Pulmonary Hemorrhage in a Positive COVID-19 Patient: A Case Report. The Cureus Journal of Medical Sciences. 2020; 12 (8): e9643. doi: 10.7759/cureus.9643
35. Moeinzadeh F, Dezfouli M, Naimi A, Shahidi S, Moradi H. Newly Diagnosed Glomerulonephritis During COVID-19 Infection Undergoing Immunosuppression Therapy, a Case Report. The Iranian Journal of Kidney Diseases. 2020; 14 (3): 239-242.
36. Uppal NN, Kello N, Shah HH, Khanin Y, De Oleo IR et al. De Novo ANCA-Associated Vasculitis With Glomerulonephritis in COVID-19. Kidney International Reports. 2020; 5 (11): 2079-2083. doi: 10.1016/j.ekir.2020.08.012
37. Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheumatology. 1997; 40 (2): 371-380. doi: 10.1002/art.1780400222
38. Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L et al. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore). 2011; 90 (1): 19-27. doi: 10/1097/ MD.0b013e318205a4c6
39. Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Annals of the Rheumatic Diseases. 2009; 68 (12): 1827-1832. doi: 10.1136/ard.2008.101279
40. Yumura W, Kobayashi S, Suka M, Hayashi T, Ito S et al. Assessment of the Birmingham vasculitis activity score in patients with MPO-ANCA-associated vasculitis: sub-analysis from a study by the Japanese Study Group for MPO-ANCA- associated vasculitis. Modern Rheumatology. 2014; 24 (2): 304- 309. doi: 10.3109/14297595.2013.854075
41. Loarce-Martos J, Garcia-Fernandez A, Lopez-Gutierrez F, Garcia-Garcia V, Calvo-Sanz L et al. High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study. Rheumatology International. 2020; 40 (12): 2015-2021. doi: 10.1007/s00296-020-04699-x
42. Yasuda H, Tsukune Y, Watanabe N, Sugimoto K, Uchimura A et al. Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma. Clinical Lymphoma, Myeloma &Leukemia. 2020; 20 (11): 774-776. doi: 10.1016/j.clml.2020.08.017
43. FAI2R /SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors. Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients. Annals of the Rheumatic Diseases. 2020; 80 (4): 527-538. doi: 10.1136/ annrheumdis-2020-218310
44. Mehta P, Porter JC, Chambers RC, Isenberg DA, Reddy V. B-cell depletion with rituximab in the COVID-19 pandemic: where do we stand? Lancet Rheumatology. 2020; 2 (10): e589-e590. doi: 10.1016/S2665-9913(20)30270
45. Nuno L, Novella Navarro M, Bonilla G, Franco-Gomez K et al. Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases. Annals of the Rheumatic Diseases. 2020; 79 (12): 1659-1661. doi: 10.1136/ annrheumdis-2020-218054
46. Schulze-Koops H, Krueger K, Vallbracht I, Hasseli R, Skapenko A. Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab. Annals of the Rheumatic Diseases. 2021; 80 (5): e67. doi: 10.1136/annrheumdis-2020-218075

APA	Armagan B, EKSIN M, Güven S, Özdemir Ulusoy B, Akyüz Dağlı P, kucuksahin o, Omma A, erden a (2022). COVID-19 course in granulomatosis with polyangiitis: single center experience with review of the literature. , 899 - 909. 10.55730/1300-0144.5389
Chicago	Armagan Berkan,EKSIN MEHMET AKIF,Güven Serdar Can,Özdemir Ulusoy Bahar,Akyüz Dağlı Pınar,kucuksahin orhan,Omma Ahmet,erden abdulsamet COVID-19 course in granulomatosis with polyangiitis: single center experience with review of the literature. (2022): 899 - 909. 10.55730/1300-0144.5389
MLA	Armagan Berkan,EKSIN MEHMET AKIF,Güven Serdar Can,Özdemir Ulusoy Bahar,Akyüz Dağlı Pınar,kucuksahin orhan,Omma Ahmet,erden abdulsamet COVID-19 course in granulomatosis with polyangiitis: single center experience with review of the literature. , 2022, ss.899 - 909. 10.55730/1300-0144.5389
AMA	Armagan B,EKSIN M,Güven S,Özdemir Ulusoy B,Akyüz Dağlı P,kucuksahin o,Omma A,erden a COVID-19 course in granulomatosis with polyangiitis: single center experience with review of the literature. . 2022; 899 - 909. 10.55730/1300-0144.5389
Vancouver	Armagan B,EKSIN M,Güven S,Özdemir Ulusoy B,Akyüz Dağlı P,kucuksahin o,Omma A,erden a COVID-19 course in granulomatosis with polyangiitis: single center experience with review of the literature. . 2022; 899 - 909. 10.55730/1300-0144.5389
IEEE	Armagan B,EKSIN M,Güven S,Özdemir Ulusoy B,Akyüz Dağlı P,kucuksahin o,Omma A,erden a "COVID-19 course in granulomatosis with polyangiitis: single center experience with review of the literature." , ss.899 - 909, 2022. 10.55730/1300-0144.5389
ISNAD	Armagan, Berkan vd. "COVID-19 course in granulomatosis with polyangiitis: single center experience with review of the literature". (2022), 899-909. https://doi.org/10.55730/1300-0144.5389

APA	Armagan B, EKSIN M, Güven S, Özdemir Ulusoy B, Akyüz Dağlı P, kucuksahin o, Omma A, erden a (2022). COVID-19 course in granulomatosis with polyangiitis: single center experience with review of the literature. Turkish Journal of Medical Sciences, 52(4), 899 - 909. 10.55730/1300-0144.5389
Chicago	Armagan Berkan,EKSIN MEHMET AKIF,Güven Serdar Can,Özdemir Ulusoy Bahar,Akyüz Dağlı Pınar,kucuksahin orhan,Omma Ahmet,erden abdulsamet COVID-19 course in granulomatosis with polyangiitis: single center experience with review of the literature. Turkish Journal of Medical Sciences 52, no.4 (2022): 899 - 909. 10.55730/1300-0144.5389
MLA	Armagan Berkan,EKSIN MEHMET AKIF,Güven Serdar Can,Özdemir Ulusoy Bahar,Akyüz Dağlı Pınar,kucuksahin orhan,Omma Ahmet,erden abdulsamet COVID-19 course in granulomatosis with polyangiitis: single center experience with review of the literature. Turkish Journal of Medical Sciences, vol.52, no.4, 2022, ss.899 - 909. 10.55730/1300-0144.5389
AMA	Armagan B,EKSIN M,Güven S,Özdemir Ulusoy B,Akyüz Dağlı P,kucuksahin o,Omma A,erden a COVID-19 course in granulomatosis with polyangiitis: single center experience with review of the literature. Turkish Journal of Medical Sciences. 2022; 52(4): 899 - 909. 10.55730/1300-0144.5389
Vancouver	Armagan B,EKSIN M,Güven S,Özdemir Ulusoy B,Akyüz Dağlı P,kucuksahin o,Omma A,erden a COVID-19 course in granulomatosis with polyangiitis: single center experience with review of the literature. Turkish Journal of Medical Sciences. 2022; 52(4): 899 - 909. 10.55730/1300-0144.5389
IEEE	Armagan B,EKSIN M,Güven S,Özdemir Ulusoy B,Akyüz Dağlı P,kucuksahin o,Omma A,erden a "COVID-19 course in granulomatosis with polyangiitis: single center experience with review of the literature." Turkish Journal of Medical Sciences, 52, ss.899 - 909, 2022. 10.55730/1300-0144.5389
ISNAD	Armagan, Berkan vd. "COVID-19 course in granulomatosis with polyangiitis: single center experience with review of the literature". Turkish Journal of Medical Sciences 52/4 (2022), 899-909. https://doi.org/10.55730/1300-0144.5389